Annual Cash & Cash Equivalents
$45.20 M
-$55.24 M-55.00%
31 December 2023
Summary:
Sangamo Therapeutics annual cash & cash equivalents is currently $45.20 million, with the most recent change of -$55.24 million (-55.00%) on 31 December 2023. During the last 3 years, it has fallen by -$86.13 million (-65.58%). SGMO annual cash & cash equivalents is now -74.73% below its all-time high of $178.87 million, reached on 31 December 2021.SGMO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$39.20 M
+$11.41 M+41.08%
30 September 2024
Summary:
Sangamo Therapeutics quarterly cash and cash equivalents is currently $39.20 million, with the most recent change of +$11.41 million (+41.08%) on 30 September 2024. Over the past year, it has dropped by -$17.31 million (-30.63%). SGMO quarterly cash and cash equivalents is now -91.61% below its all-time high of $467.44 million, reached on 30 June 2020.SGMO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -55.0% | -30.6% |
| 3 y3 years | -65.6% | -77.8% |
| 5 y5 years | -67.8% | -65.7% |
SGMO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -74.7% | at low | -78.1% | +41.1% |
| 5 y | 5 years | -74.7% | at low | -91.6% | +41.1% |
| alltime | all time | -74.7% | >+9999.0% | -91.6% | +550.1% |
Sangamo Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $39.20 M(+41.1%) |
| June 2024 | - | $27.79 M(-48.9%) |
| Mar 2024 | - | $54.42 M(+20.4%) |
| Dec 2023 | $45.20 M(-55.0%) | $45.20 M(-20.0%) |
| Sept 2023 | - | $56.51 M(-15.4%) |
| June 2023 | - | $66.83 M(-14.6%) |
| Mar 2023 | - | $78.24 M(-22.1%) |
| Dec 2022 | $100.44 M(-43.8%) | $100.44 M(+6.2%) |
| Sept 2022 | - | $94.57 M(-19.7%) |
| June 2022 | - | $117.70 M(-2.1%) |
| Mar 2022 | - | $120.26 M(-32.8%) |
| Dec 2021 | $178.87 M(+36.2%) | $178.87 M(+1.1%) |
| Sept 2021 | - | $176.95 M(+4.2%) |
| June 2021 | - | $169.88 M(+38.1%) |
| Mar 2021 | - | $122.97 M(-6.4%) |
| Dec 2020 | $131.33 M(+63.3%) | $131.33 M(-49.4%) |
| Sept 2020 | - | $259.39 M(-44.5%) |
| June 2020 | - | $467.44 M(+445.1%) |
| Mar 2020 | - | $85.75 M(+6.6%) |
| Dec 2019 | $80.43 M(-42.7%) | $80.43 M(-29.6%) |
| Sept 2019 | - | $114.29 M(-32.5%) |
| June 2019 | - | $169.22 M(+109.0%) |
| Mar 2019 | - | $80.97 M(-42.3%) |
| Dec 2018 | $140.42 M(+181.8%) | $140.42 M(+257.3%) |
| Sept 2018 | - | $39.30 M(-33.8%) |
| June 2018 | - | $59.41 M(+93.5%) |
| Mar 2018 | - | $30.71 M(-38.4%) |
| Dec 2017 | $49.83 M(+125.9%) | $49.83 M(+66.7%) |
| Sept 2017 | - | $29.89 M(-57.2%) |
| June 2017 | - | $69.84 M(+277.8%) |
| Mar 2017 | - | $18.49 M(-16.2%) |
| Dec 2016 | $22.06 M(-68.2%) | $22.06 M(-21.2%) |
| Sept 2016 | - | $27.99 M(+116.0%) |
| June 2016 | - | $12.96 M(-60.8%) |
| Mar 2016 | - | $33.01 M(-52.5%) |
| Dec 2015 | $69.48 M(+1052.3%) | $69.48 M(+102.6%) |
| Sept 2015 | - | $34.29 M(+218.4%) |
| June 2015 | - | $10.77 M(-57.4%) |
| Mar 2015 | - | $25.26 M(+318.8%) |
| Dec 2014 | $6.03 M(-40.8%) | $6.03 M(-46.2%) |
| Sept 2014 | - | $11.21 M(-88.7%) |
| June 2014 | - | $99.27 M(-21.7%) |
| Mar 2014 | - | $126.82 M(+1145.1%) |
| Dec 2013 | $10.19 M(-53.0%) | $10.19 M(-87.3%) |
| Sept 2013 | - | $80.31 M(+566.4%) |
| June 2013 | - | $12.05 M(-1.0%) |
| Mar 2013 | - | $12.18 M(-43.8%) |
| Dec 2012 | $21.68 M | $21.68 M(+58.0%) |
| Sept 2012 | - | $13.72 M(-25.7%) |
| June 2012 | - | $18.48 M(-24.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $24.49 M(+46.1%) |
| Dec 2011 | $16.77 M(+55.5%) | $16.77 M(-22.6%) |
| Sept 2011 | - | $21.67 M(+157.3%) |
| June 2011 | - | $8.42 M(+22.4%) |
| Mar 2011 | - | $6.88 M(-36.2%) |
| Dec 2010 | $10.78 M(-49.0%) | $10.78 M(+19.1%) |
| Sept 2010 | - | $9.05 M(-29.2%) |
| June 2010 | - | $12.79 M(+4.8%) |
| Mar 2010 | - | $12.20 M(-42.3%) |
| Dec 2009 | $21.16 M(+9.0%) | $21.16 M(+50.1%) |
| Sept 2009 | - | $14.10 M(-4.6%) |
| June 2009 | - | $14.77 M(+0.9%) |
| Mar 2009 | - | $14.64 M(-24.6%) |
| Dec 2008 | $19.41 M(+58.1%) | $19.41 M(+122.0%) |
| Sept 2008 | - | $8.74 M(+1.0%) |
| June 2008 | - | $8.66 M(-12.9%) |
| Mar 2008 | - | $9.94 M(-19.0%) |
| Dec 2007 | $12.28 M(-3.4%) | $12.28 M(-27.3%) |
| Sept 2007 | - | $16.89 M(+74.7%) |
| June 2007 | - | $9.67 M(-12.3%) |
| Mar 2007 | - | $11.03 M(-13.2%) |
| Dec 2006 | $12.70 M(-31.4%) | $12.70 M(-21.2%) |
| Sept 2006 | - | $16.12 M(-44.1%) |
| June 2006 | - | $28.84 M(+115.2%) |
| Mar 2006 | - | $13.40 M(-27.6%) |
| Dec 2005 | $18.51 M(+114.5%) | $18.51 M(+75.8%) |
| Sept 2005 | - | $10.53 M(+36.6%) |
| June 2005 | - | $7.71 M(+1.2%) |
| Mar 2005 | - | $7.62 M(-11.7%) |
| Dec 2004 | $8.63 M(-12.0%) | $8.63 M(+30.3%) |
| Sept 2004 | - | $6.62 M(-14.9%) |
| June 2004 | - | $7.78 M(-18.2%) |
| Mar 2004 | - | $9.51 M(-3.0%) |
| Dec 2003 | $9.80 M(-44.4%) | $9.80 M(-19.0%) |
| Sept 2003 | - | $12.10 M(+23.5%) |
| June 2003 | - | $9.80 M(-22.1%) |
| Mar 2003 | - | $12.59 M(-28.6%) |
| Dec 2002 | $17.64 M(+130.8%) | $17.64 M(+14.9%) |
| Sept 2002 | - | $15.35 M(-53.6%) |
| June 2002 | - | $33.06 M(+3.3%) |
| Mar 2002 | - | $32.01 M(+318.8%) |
| Dec 2001 | $7.64 M(-24.7%) | $7.64 M(-64.0%) |
| Sept 2001 | - | $21.20 M(+39.9%) |
| June 2001 | - | $15.16 M(-5.5%) |
| Mar 2001 | - | $16.05 M(+58.1%) |
| Dec 2000 | $10.15 M(+3283.7%) | $10.15 M(+11.0%) |
| Sept 2000 | - | $9.14 M(-76.9%) |
| June 2000 | - | $39.59 M(+273.7%) |
| Mar 2000 | - | $10.59 M |
| Dec 1999 | $300.00 K | - |
FAQ
- What is Sangamo Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual cash & cash equivalents year-on-year change?
- What is Sangamo Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Sangamo Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SGMO is $45.20 M
What is the all time high annual cash & cash equivalents for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual cash & cash equivalents is $178.87 M
What is Sangamo Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SGMO annual cash & cash equivalents has changed by -$55.24 M (-55.00%)
What is Sangamo Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SGMO is $39.20 M
What is the all time high quarterly cash and cash equivalents for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly cash and cash equivalents is $467.44 M
What is Sangamo Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SGMO quarterly cash and cash equivalents has changed by -$17.31 M (-30.63%)